Pharmacologic properties of some derivatives of N- (2-carboxyphenyl) -4-phenoxyacetamide
Cebo, B.; Krupińska, J.; Mazur, J.
Archivum Immunologiae et Therapiae Experimentalis 27(3): 415-424
1979
ISSN/ISBN: 0004-069X PMID: 314282 Document Number: 146050
Three new prostaglandin (PG) synthetase inhibitors [N-(2-carboxy-4-chlorophenyl)-phenoxyacetamide (ZR 29), N-(2-carboxy-4-chlorophenyl)-5-bromophenoxyacetamide (ZR-32), N-(2-carboxy-4-chlorophenyl)-4'-nitrophenoxyacetamide (ZR-35)] in doses of 30-100-200 mg/kg orally inhibited edema in an acute inflammatory model in rats. ZR-32 inhibited formation of granuloma. In the chronic inflammatory model, ZR-32 exerted strongest activity in the 2nd and 3rd wk. ZR-32 demonstrated strong analgesic activity in the test of stimulation with electric current and in the hot plate test, besides antipyretic activity. Both compounds given weekly irritated the gastric mucosa. The compounds had no effect on the CNS. Their acute toxicity was substantially lower than that of acetylsalicylic acid and indomethacin.